目錄:愛必信（上海）生物科技有限公司>>生化試劑>>小分子化合物>> abs47028249CH5183284 (Debio-1347) 1265229-25-1
| 參考價(jià) | ￥824-￥4217 |
參考價(jià)：￥824 ~ ￥4217
2mg 5mg 10mg >
CAS:1265229-25-1 純度:98% 分子量:356.38 分子式:C20H16N6O 供貨周期:現(xiàn)貨 規(guī)格:2mg 貨號:abs47028249 應(yīng)用領(lǐng)域:化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 主要用途:is a selective and orally available FGFR
>| 2mg | 824元 | 999mg可售 |
| 5mg | 1237元 | 999mg可售 |
| 10mg | 2159元 | 999mg可售 |
更新時(shí)間：2026-01-26 13:26:03瀏覽次數(shù)：919評價(jià)
聯(lián)系我們時(shí)請說明是化工儀器網(wǎng)上看到的信息，謝謝!
| CAS | 1265229-25-1 | 純度 | 98% |
|---|---|---|---|
| 分子量 | 356.38 | 分子式 | C20H16N6O |
| 供貨周期 | 現(xiàn)貨 | 規(guī)格 | 2mg |
| 貨號 | abs47028249 | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
| 主要用途 | is a selective and orally available FGFR |
CH5183284 (Debio-1347) 1265229-25-1
| 產(chǎn)品描述 | |
| 描述 | CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1. |
| 純度 | 98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 可溶性/溶解性 | DMSO:71 mg/mL (199.22 mM) |
| 生物活性 | |
| 靶點(diǎn) | FGFR2 ,FGFR1 ,FGFR3 ,FGFR4 |
| In vitro(體外研究) | In cell-based assay, CH5183284 prevents autophosphorylation of FGFR1, FGFR2, and FGFR3 at 100 to 300 nM in the DMS114 (FGFR1 amplification), SNU-16 (FGFR2 amplification), and KMS11 cell lines. CH5183284 thus produces selective antiproliferative activity against cancer cell lines harboring genetic alterations in FGFR. CH5183284 also inhibit FGFR2 harboring one type of the gatekeeper mutation (V564F) that causes resistance to other FGFR inhibitors. |
| In vivo(體內(nèi)研究) | CH5183284 (100 mg/kg/day, p.o.) shows selective and significant antitumor activity against xenografts with FGFR genetic alterations such as KG1 (leukemia, FGFR1OP-FGFR1 fusion), SNU-16 (gastric cancer, FGFR2 amplification), MFE-280 (endometrial cancer, FGFR2 S252W mutation), UM-UC-14 (bladder cancer, FGFR3 S249C mutation), and RT112/84 (bladder cancer, FGFR3-TACC3 fusion). |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | CancerGrowth factorsFGF CancerSignal transductionProtein phosphorylationTyrosine kinasesReceptor tyrosine kinases CardiovascularAngiogenesisGrowth FactorsFGFFGF Receptors Developmental BiologyLineage specificationEctoderm NeuroscienceDevelopment NeuroscienceNeurology processNeurogenesis Signal TransductionGrowth Factors/HormonesFGF Signal TransductionProtein PhosphorylationTyrosine KinasesReceptor Tyrosine Kinases Stem CellsLineage MarkersEctoderm Drug DiscoverySmall Molecule DrugLead Compound Discovery |
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)
10
化工儀器網(wǎng)